FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W173906711> ?p ?o ?g. }

• W173906711 endingPage "B4475" @default.
• W173906711 startingPage "B4475" @default.
• W173906711 abstract "Today, sentinel lymph node dissection (SLND) has replaced axillary lymph node dissection (ALND) as standard procedure for staging of the axilla in the treatment of breast cancer. SLND can accurately stage the axilla by removing on average only two lymph nodes. Only in case of metastatic spread to sentinel nodes an ALND is offered. Removing fewer nodes has made more extensive histopathological examinations of the lymph nodes possible and as a consequence more metastases are found. This has resulted in stage migration. Based on data from the nationwide Danish Breast Cancer Cooperative Group (DBCG) database we have estimated the magnitude and therapeutic consequences of this stage migration in Denmark by comparing the distribution of lymph node metastases in breast cancer patients operated in 1993-1996 and 2005-2008; before and after introducing SLND. The proportion of patients having macrometastases was not significantly different in the two periods, whereas the proportion of patients with micrometastases increased significantly from 5.1% to 9.0%. However, the proportion of patients offered adjuvant systemic treatment due to positive nodal status as the only high-risk criterion did only increase from 7.8% to 8.8%, when estimated using today´s criteria for risk-allocation, because nodal status is now less important in risk-allocation. In general, only 15-20% of patients with micrometastases and 10-15% of patients with isolated tumor cells (ITC) in sentinel node have further metastatic spread to non-sentinel nodes (NSN). Thus, the majority of these patients does not benefit from additional ALND but still run the risk of arm morbidity. Based on data from the DBCG database, we have developed two models to predict NSN metastases in breast cancer patients with micrometastases or ITC in the sentinel node. A total number of 304 breast cancer patients with ITC and 1577 patients with micrometastases in sentinel node operated in 2001-2008 with SLND and subsequent ALND were identified in the database. In patients with ITC in sentinel node the risk of NSN metastases was significantly associated with younger age at diagnosis, increasing tumor size and increasing proportion of positive sentinel nodes in a multivariate analysis. If patients were ≥ 40 years at diagnosis with tumor size ≤ 2 cm as well as one or more negative sentinel nodes, NSN metastases were found in only 2%. Omission of ALND in this group would spare 1/3 of patients with ITC in sentinel node for an ALND. In patients with micrometastases in sentinel node the risk of NSN metastases was significantly associated with increasing tumor size, lymphovascular invasion, negative hormone receptor status, location of tumor in the upper lateral quadrant of the breast and increasing proportion of positive sentinel nodes in a multivariate analysis. However, a model based on these traditional prognostic markers could not identify a subgroup of patients with a risk of NSN metastases less than 10%. We then investigated whether the biochemical prognostic markers TIMP-1, Ki67 and HER2 could support the model. In a matched case-control study 25 cases with micrometastases in sentinel node and additional metastatic spread to NSN were compared to 50 matched controls with micrometastases in sentinel node but without NSN metastases. Despite being prognostic markers in breast cancer, we found no significant differences in the expression of these three biochemical markers between patients with and without NSN metastases. Not all NSN metastases will become clinically relevant, making ALND redundant in many breast cancer patients. Accordingly, there is a trend towards omission of ALND in breast cancer patients with minimal metastatic disease in sentinel node. As a result, a tool is needed to identify a group of patients with high risk of recurrence, where ALND should still be offered. In our model a small group of patients with micrometastases had a high risk of NSN metastases on nearly 40%, comparable to patients with macrometastases, indicating that ALND may still be recommended in this subgroup in the future." @default.
• W173906711 created "2016-06-24" @default.
• W173906711 creator A5064469163 @default.
• W173906711 date "2012-07-01" @default.
• W173906711 modified "2023-09-23" @default.
• W173906711 title "Staging of women with breast cancer after introduction of sentinel node guided axillary dissection." @default.
• W173906711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22759850" @default.
• W173906711 hasPublicationYear "2012" @default.
• W173906711 type Work @default.
• W173906711 sameAs 173906711 @default.
• W173906711 citedByCount "6" @default.
• W173906711 countsByYear W1739067112014 @default.
• W173906711 countsByYear W1739067112017 @default.
• W173906711 countsByYear W1739067112018 @default.
• W173906711 countsByYear W1739067112020 @default.
• W173906711 crossrefType "journal-article" @default.
• W173906711 hasAuthorship W173906711A5064469163 @default.
• W173906711 hasConcept C121608353 @default.
• W173906711 hasConcept C126322002 @default.
• W173906711 hasConcept C126838900 @default.
• W173906711 hasConcept C141071460 @default.
• W173906711 hasConcept C142724271 @default.
• W173906711 hasConcept C143998085 @default.
• W173906711 hasConcept C146357865 @default.
• W173906711 hasConcept C151730666 @default.
• W173906711 hasConcept C179671157 @default.
• W173906711 hasConcept C2775862295 @default.
• W173906711 hasConcept C2776608951 @default.
• W173906711 hasConcept C2779720271 @default.
• W173906711 hasConcept C2780212769 @default.
• W173906711 hasConcept C2780849966 @default.
• W173906711 hasConcept C2908949552 @default.
• W173906711 hasConcept C530470458 @default.
• W173906711 hasConcept C71924100 @default.
• W173906711 hasConcept C86803240 @default.
• W173906711 hasConceptScore W173906711C121608353 @default.
• W173906711 hasConceptScore W173906711C126322002 @default.
• W173906711 hasConceptScore W173906711C126838900 @default.
• W173906711 hasConceptScore W173906711C141071460 @default.
• W173906711 hasConceptScore W173906711C142724271 @default.
• W173906711 hasConceptScore W173906711C143998085 @default.
• W173906711 hasConceptScore W173906711C146357865 @default.
• W173906711 hasConceptScore W173906711C151730666 @default.
• W173906711 hasConceptScore W173906711C179671157 @default.
• W173906711 hasConceptScore W173906711C2775862295 @default.
• W173906711 hasConceptScore W173906711C2776608951 @default.
• W173906711 hasConceptScore W173906711C2779720271 @default.
• W173906711 hasConceptScore W173906711C2780212769 @default.
• W173906711 hasConceptScore W173906711C2780849966 @default.
• W173906711 hasConceptScore W173906711C2908949552 @default.
• W173906711 hasConceptScore W173906711C530470458 @default.
• W173906711 hasConceptScore W173906711C71924100 @default.
• W173906711 hasConceptScore W173906711C86803240 @default.
• W173906711 hasIssue "7" @default.
• W173906711 hasLocation W1739067111 @default.
• W173906711 hasOpenAccess W173906711 @default.
• W173906711 hasPrimaryLocation W1739067111 @default.
• W173906711 hasRelatedWork W2019617125 @default.
• W173906711 hasRelatedWork W2024992326 @default.
• W173906711 hasRelatedWork W2036977094 @default.
• W173906711 hasRelatedWork W2093959080 @default.
• W173906711 hasRelatedWork W2130546155 @default.
• W173906711 hasRelatedWork W2261376874 @default.
• W173906711 hasRelatedWork W2283682469 @default.
• W173906711 hasRelatedWork W2339834749 @default.
• W173906711 hasRelatedWork W2960185863 @default.
• W173906711 hasRelatedWork W2187009903 @default.
• W173906711 hasVolume "59" @default.
• W173906711 isParatext "false" @default.
• W173906711 isRetracted "false" @default.
• W173906711 magId "173906711" @default.
• W173906711 workType "article" @default.